Persistence, half-life and tolerance are different questions. A substance can leave a measurable biological consequence after its concentration changes, while a person’s perceived effect can fluctuate for reasons unrelated to tolerance. Using one term to explain all three can make an unsupported cycling claim seem scientific.
A rat ischemic-injury study assessed later spatial learning after an earlier period of Semax administration. It reported recovery of performance within that experimental model. That finding concerns a specific injury and behavioral task; it does not establish permanent cognitive enhancement in healthy people or a reliable duration of benefit for a research product.
The rat distribution and degradation experiment addresses a different question: where labeled peptide-related material appeared and how it was broken down. Its results cannot supply a validated human half-life or tell a reader how long a subjective improvement should last. Exposure and clinical duration need to be measured rather than treated as identical.
Online explanations about receptor burnout add another unproven step. A declining subjective effect does not, by itself, identify a receptor-level mechanism. Changes in task demands, expectations, sleep or other exposures could contribute. Equally, the absence of an obvious decline cannot establish that prolonged use is safe.
To validate a repeated-use strategy, a study would need to compare clearly defined approaches, measure meaningful outcomes and assess harms over an appropriate interval. The sources summarized here do not provide that evidence. Breaks, alternating compounds or increasing exposure are not conclusions that can be derived from the animal findings.
A physician reviewing a duration claim should ask what actually persisted: a symptom rating, task performance, a biomarker or simply the person’s recollection. The quality of the comparison and the length of follow-up determine how much confidence is justified. A specific number of days in a forum report cannot replace that assessment.
This appraisal is based on primary abstracts. It preserves the possibility that experimental effects can outlast an initial exposure while rejecting a stronger conclusion the evidence does not establish. Permanent benefit, prevention of tolerance and a safe cycling plan remain separate claims, not automatic consequences of the research reviewed here.